| Literature DB >> 35280803 |
Yan Gui1,2, Dongmei Huang3, Yun Hou1, Xudong Wei4,2,5, Jinming Zhang3, Junyi Wang3.
Abstract
Background: The incidence of papillary thyroid carcinoma (PTC) in children and adolescents has increased, but the data on long-term outcomes are limited. There are few literatures on the clinicopathological characteristics and prognosis of PTC in children and adolescents in China. Therefore, it is necessary to identify clinicopathological features to precisely predict clinical prognosis and to help choose the optimal method and perform the best therapeutic regimen.Entities:
Keywords: children and adolescents; lymph node metastases; papillary thyroid carcinoma; prognosis; recurrence
Year: 2022 PMID: 35280803 PMCID: PMC8909140 DOI: 10.3389/fonc.2022.833775
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Characteristics of the study patients.
| Characteristics | Value | Characteristics | Value |
|---|---|---|---|
| Age at diagnosis | Bilaterality | ||
| <14 years | 36 (37.9) | Yes | 33 (34.7) |
| 14–18 years | 59 (62.1) | No | 62 (65.3) |
| Gender | Central LNM | ||
| Female | 64 (67.4) | Yes | 84 (88.4) |
| Male | 31 (32.6) | No | 11 (11.6) |
| Preoperative TPOAb level | Lateral LNM | ||
| Positive | 29 (30.5) | Yes | 66 (69.5) |
| Negative | 66 (69.5) | No | 29 (30.5) |
| Preoperative TgAb level | N stage | ||
| Positive | 25 (26.3) | N0 | 6 (6.3) |
| Negative | 70 (73.7) | N1a | 23 (24.2) |
| Preoperative TSH level | N1b | 66 (69.5) | |
| Positive | 19 (20.0) | Surgical approach | |
| Negative | 76 (80.0) | Total bilateral thyroidectomy | 41 (43.2) |
| Preoperative Tg level | Ipsilateral glandular lobe plus isthmus resection | 42 (44.2) | |
| Positive | 34 (35.8) | Subtotal thyroidectomy | 12 (12.6) |
| Negative | 61 (64.2) | Lymph node dissection | |
| Maximal tumor size | Unilateral CLND | 18 (18.9) | |
| ≤2 cm | 40 (42.1) | Unilateral MRND | 28 (29.5) |
| >2 cm | 55 (57.9) | Unilateral MRND, plus contralateral CLND | 12 (12.6) |
| T stage | Bilateral CLND | 6 (6.3) | |
| T1a | 5 (5.3) | Bilateral MRND | 31 (32.6) |
| T1b | 35 (36.8) | No. of total LND | 39 (0-136) |
| T2 | 49 (51.6) | No. of total LNM | 11 (0-44) |
| T3 | 6 (6.3) | ATA pediatric risk | |
| Multifocality | Low | 25 (26.3) | |
| Yes | 57 (60.0) | Intermediate | 23 (24.2) |
| No | 38 (40.0) | High | 47 (49.5) |
| Extrathyroidal extension | Recurrence | ||
| Yes | 67 (70.5) | Yes | 29 (30.5) |
| No | 28 (29.5) | No | 66 (69.5) |
TPOAb, thyroid peroxidase antibody; TgAb, thyroglobulin antibody; TSH, thyroid-stimulating hormone; Tg, thyroglobulin; LNM, lymph node metastases; CLND, central lymph node dissection; MRND, modified radical neck dissection; LND, lymph node dissection; ATA, American Thyroid Association.
Comparison of clinicopathological features of PTC in children and adolescents with different age groups.
| Variables | <14 years (n = 36) | 14–18 years (n = 59) | p-Value |
|---|---|---|---|
| Gender | |||
| Male | 12 (33.3) | 19 (32.2) | 0.909 |
| Female | 24 (66.7) | 40 (67.8) | |
| Maximal tumor size | |||
| ≤2 cm | 11 (30.6) | 29 (49.2) | 0.075 |
| >2 cm | 25 (69.4) | 30 (50.8) | |
| T stage | |||
| T1a | 0 (0.0) | 5 (8.5) | 0.167 |
| T1b | 11 (30.6) | 24 (40.7) | |
| T2 | 22 (61.1) | 27 (45.8) | |
| T3 | 3 (8.3) | 3 (5.1) | |
| Central LNM | |||
| Yes | 35 (97.2) | 49 (83.1) | 0.078 |
| No | 1 (2.8) | 10 (16.9) | |
| Lateral LNM | |||
| Yes | 29 (80.6) | 37 (62.7) | 0.067 |
| No | 7 (19.4) | 22 (37.2) | |
| N stage | |||
| N0 | 1 (2.8) | 5 (8.5) | 0.209 |
| N1a | 6 (16.7) | 17 (28.8) | |
| N1b | 29 (80.6) | 37 (62.7) | |
| Multifocality | |||
| Yes | 27 (75.0) | 30 (50.8) | 0.020 |
| No | 9 (25.0) | 29 (49.2) | |
| Extrathyroidal extension | |||
| Yes | 25 (69.4) | 42 (71.2) | 0.857 |
| No | 11 (30.6) | 17 (28.8) | |
| Bilaterality | |||
| Yes | 16 (44.4) | 42 (71.2) | 0.121 |
| No | 20 (55.6) | 17 (28.8) | |
| Preoperative TSH level | 6.6 ± 16.5 | 2.9 ± 2.1 | 0.032 |
| Preoperative Tg level | 125.3 ± 203.5 | 129.3 ± 166.9 | 0.419 |
| Surgical approach | |||
| Total bilateral thyroidectomy | 23 (63.9) | 18 (30.5) | <0.001 |
| Ipsilateral glandular lobe plus isthmus resection | 7 (19.4) | 35 (59.3) | |
| Subtotal thyroidectomy | 6 (16.7) | 6 (10.2) | |
| Lymph node dissection | |||
| Unilateral CLND | 4 (11.1) | 14 (23.7) | 0.003 |
| Unilateral MRND | 7 (19.4) | 21 (35.6) | |
| Unilateral MRND, plus contralateral CLND | 2 (5.6) | 10 (16.9) | |
| Bilateral CLND | 3 (8.3) | 3 (5.1) | |
| Bilateral MRND | 20 (55.6) | 11 (18.6) | |
| Number of central LND | 12.6 ± 6.8 | 7.9 ± 5.2 | <0.001 |
| Number of lateral LND | 45.9 ± 33.8 | 26.2 ± 25.3 | 0.002 |
| Number of LND | 58.5 ± 37.0 | 34.1 ± 27.3 | 0.001 |
| Number of central LN metastases | 7.1 ± 4.3 | 4.6 ± 3.8 | 0.005 |
| Number of lateral LN metastases | 10.7 ± 8.6 | 5.3 ± 6.7 | 0.002 |
| Number of LN metastases | 17.7 ± 11.8 | 10.0 ± 8.6 | 0.001 |
| ATA pediatric risk | 0.089 | ||
| Low | 7 (19.4) | 18 (30.5) | |
| Intermediate | 6 (16.7) | 17 (28.8) | |
| High | 23 (63.9) | 24 (40.7) | |
| Recurrence | |||
| Yes | 19 (52.8) | 10 (16.9) | <0.001 |
| No | 17 (47.2) | 49 (83.1) |
LNM, lymph node metastases; TSH, thyroid-stimulating hormone; Tg, thyroglobulin; CLND, central lymph node dissection; MRND, modified radical neck dissection; LND, lymph node dissection; ATA, American Thyroid Association.
Figure 1The disease-free survival (DFS) curves of risk factors for recurrence in children and adolescents with papillary thyroid carcinoma (PTC). (A) The DFS curves of age at diagnosis in children and adolescents with PTC. (B) The DFS curves of maximal tumor size in children and adolescents with PTC. (C) The DFS curves of lateral LN metastases in children and adolescents with PTC. (D) The DFS curves of ATA pediatric in children and adolescents with PTC. (E) The DFS curves of Preoperative TSH level in children and adolescents with PTC. (F) The DFS curves of Preoperative Tg level in children and adolescents with PTC.
Univariate and multivariate analyses of risk factors of cervical lymph node metastases.
| Variables | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| OR (95%) | p-Value | OR | 95% CI | p-Value | |
|
| |||||
| Maximal tumor size >2 cm | 4.333 (1.071–17.539) | 0.040 | |||
| T stage | 2.647 (1.031–6.800) | 0.043 | |||
| Multifocality | 1.950 (0.550–6.915) | 0.301 | |||
| Extrathyroidal extension | 0.885 (0.217–3.614) | 0.865 | |||
| Bilaterality | 0.600 (0.168–2.138) | 0.431 | |||
|
| |||||
| Maximal tumor size >2 cm | 4.071 (1.615–10.262) | 0.003 | |||
| T stage | 2.763 (1.361–5.607) | 0.005 | |||
| Central LNM | 3.183 (0.885–11.447) | 0.076 | |||
| Number of central LNM | 8.482 (2.651–27.136) | <0.001 | |||
| Multifocality | 2.462 (1.008–6.012) | 0.048 | 6.237 | 1.747–22.266 | 0.005 |
| Extrathyroidal extension | 1.113 (0.430–2.879) | 0.825 | |||
| Bilaterality | 1.270 (0.500–3.228) | 0.616 | |||
OR, odds ratio; LNM, lymph node metastases.
Factors related to the number of positive cervical lymph node metastasis (≤5 vs. >5).
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
|
| ||||||
| Gender | 0.433 | 0.181–1.039 | 0.061 | |||
| Age at diagnosis | 0.326 | 0.138–0.771 | 0.011 | |||
| Maximal tumor size >2 cm | 3.405 | 1.420–8.169 | 0.006 | |||
| T stage | 3.193 | 1.563–6.524 | 0.001 | |||
| Multifocality | 4.431 | 1.776–11.053 | 0.001 | 3.575 | 1.331–9.601 | 0.011 |
| Extrathyroidal extension | 1.331 | 0.542–3.266 | 0.533 | |||
| Bilaterality | 1.572 | 0.672–3.681 | 0.297 | |||
| Preoperative TPOAb level | 0.690 | 0.283–1.684 | 0.415 | |||
| Preoperative TgAb level | 0.498 | 0.190–1.304 | 0.156 | |||
| Preoperative TSH level | 1.528 | 0.557–4.191 | 0.410 | |||
| Preoperative Tg level | 1.08 | 0.462–2.526 | 0.859 | |||
|
| ||||||
| Gender | 0.727 | 0.307–1.719 | 0.467 | |||
| Age at diagnosis | 0.388 | 0.165–0.912 | 0.030 | |||
| Maximal tumor size >2 cm | 6.167 | 2.480–15.331 | <0.001 | |||
| T stage | 3.558 | 1.724–7.340 | 0.001 | |||
| Central LNM | 2.933 | 0.728–11.827 | 0.130 | |||
| Number of central LNM | 6.517 | 2.639–16.092 | <0.001 | |||
| Multifocality | 4.208 | 1.739–10.183 | 0.001 | 3.175 | 1.171–8.608 | 0.023 |
| Extrathyroidal extension | 0.971 | 0.402–2.345 | 0.947 | |||
| Bilaterality | 1.366 | 0.585–3.187 | 0.471 | |||
| Preoperative TPOAb level | 0.933 | 0.390–2.236 | 0.877 | |||
| Preoperative TgAb level | 0.742 | 0.296–1.859 | 0.524 | |||
| Preoperative TSH level | 2.676 | 0.920–7.786 | 0.071 | |||
| Preoperative Tg level | 1.994 | 0.844–4.713 | 0.116 | |||
OR, odds ratio; LNM, lymph node metastases; TPOAb, thyroid peroxidase antibody; TgAb, thyroglobulin antibody; TSH, thyroid-stimulating hormone; Tg, thyroglobulin.
Cox proportional hazards regression analysis for variables associated with PTC recurrence.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
| <14 years old | 4.150 | 1.924–8.953 | <0.001 | 4.859 | 1.912–12.350 | 0.001 |
| Positive preoperative TPOAb level | 0.419 | 0.160–1.100 | 0.077 | |||
| Positive preoperative TgAb level | 0.538 | 0.205–1.411 | 0.208 | |||
| Positive preoperative TSH level | 2.961 | 1.389–6.314 | 0.005 | 2.416 | 1.077–5.420 | 0.032 |
| Positive preoperative Tg level | 2.068 | 0.994–4.301 | 0.052 | |||
| Maximal tumor size >2 cm | 2.61 | 1.113–6.119 | 0.027 | |||
| T stage | 1.691 | 0.985–2.905 | 0.057 | |||
| Number of central LNM>5 | 2.719 | 1.262–5.855 | 0.011 | |||
| Number of lateral LNM>5 | 5.031 | 2.044–12.388 | <0.001 | |||
| Lateral LNM | 4.322 | 1.306–14.309 | 0.017 | |||
| N stage | 3.911 | 1.270–12.044 | 0.017 | |||
| Multifocality | 1.982 | 0.878–4.477 | 0.100 | |||
| Extrathyroidal extension | 0.950 | 0.418–2.158 | 0.903 | |||
| Bilaterality | 0.556 | 0.237–1.302 | 0.176 | |||
| ATA pediatric risk | 3.056 | 1.591–5.871 | 0.001 | |||
HR, hazard ratio; TPOAb, thyroid peroxidase antibody; TgAb, thyroglobulin antibody; TSH, thyroid-stimulating hormone; Tg, thyroglobulin; LNM, lymph node metastases; ATA, American Thyroid Association.